Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition ...

Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition strengthens its position in the U.S. market, with significant market share ...

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like ...

Biosimilar substitution is automatic ... Serious players in these markets such as Ranbaxy, DRL, Biocon, and Reliance Life Sciences are only planning to enter into the European markets either ...

Feb 03, 2025 14:05 Biocon Posts Rs 25 Crore Profit in Q3 FY25 Biocon reported a net profit of Rs 25 crore in Q3 FY25, driven by growth in biosimilars and research services. The company's total income ...

Fulphila was co-developed through a collaboration between Mylan and India’s Biocon that has produced 11 biologic and insulin products, including the FDA-approved Ogivri, a biosimilar version of ...

Nandita Vijayasimha, Bengaluru Friday, February 14, 2025, 08:00 Hrs [IST] ...

Investors need to recognize Karnataka as destination where investments grow & innovation thrives: Kiran Mazumdar-Shaw: Nandita Vijayasimha, Bengaluru Thursday, February 13, 2025, ...